ClinicalTrials.gg
Active, not recruitingNCT04076059China ARCHESUpdated Oct 20, 2026Results posted

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A Phase 3 interventional study of Enzalutamide and Placebo in Metastatic Hormone Sensitive Prostate Cancer, sponsored by Astellas (Beijing) Pharmaceutical R&D Co., Ltd.. Active, not recruiting at 28 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Astellas (Beijing) Pharmaceutical R&D Co., Ltd. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
30th of 125
180 · median 52
Started
2019
with 6 others
Phase 3
16 of 125
1 open now
Primary completion
2022-11
later than 4 of 37 live
Registered
96th of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 30th largest by enrollment, is one of 7 that started in 2019, is one of 16 in phase 3, reaches primary completion later than 4 of the 37 other live ones, and was the 96th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.

03

Conditions studied

  • Metastatic Hormone Sensitive Prostate Cancer

Browse trials for

Keywords

  • Metastatic hormone sensitive prostate cancer
  • Androgen Deprivation Therapy (ADT)
  • Xtandi
  • MDV3100
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Double Blind treatment Phase:

  • Subject is diagnosed with or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
  • Subject has prostate cancer documented by positive bone scan (for bone disease) or measurable metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
  • Once randomized at day 1, subject must maintain androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).
  • Subject has an (ECOG) performance status of 0 or 1 at screening.
  • Subject has an estimated of ≥ 12 months.
  • Subject is able to swallow the study drug and comply with study requirements.
  • A sexually active male subject with female partner(s) who is of is eligible if:

    • Agrees to use a male condom starting at screening and continue throughout the study treatment and for at least 3 months after the last dose of study drug. If the male subject has not had a vasectomy or is not sterile at least 6 months prior to screening his female partner(s) is utilizing 1 form of highly effective per locally accepted standards starting at screening and continue throughout study treatment and for at least 3 months after the male subject receives his last dose of study drug.
  • Subject must agree to abstinence or use a condom throughout the study period and for at least 3 months after the last dose of study drug if engaging in sexual intercourse with a pregnant or breastfeeding partner(s).
  • Subject must agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drug.
  • Subject agrees not to participate in another interventional study while on treatment.

Open Label Phase:

  • Before the sponsor's formal determination on study-wide unblinding, includes the subject who has evidence of radiographic progression as confirmed during the double-blind treatment (only apply to the subject in the placebo arm).
  • Subject has not met any of the discontinuation criteria in the main protocol. Subject in the placebo arm who achieved confirmed radiographic progression in the double-blinded period is eligible.
  • Subject is willing to maintain ADT with LHRH agonist or antagonist or has had a bilateral orchiectomy
  • Subject is able to swallow enzalutamide capsules whole and to comply with study requirements throughout the study
  • Subject and subject's female partner agree to follow contraception and sperm donation requirements in main protocol
  • IRB-/IEC-approved written and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  • Subject is considered an adult according to local regulation at the time of signing informed consent.
  • After the sponsor's formal determination on study-wide unblinding, includes the subject who is randomized to receive treatment in the double-blind period (apply to all subjects).

Exclusion criteria

Exclusion Criteria:

Double-Blind Treatment Phase:

  • Subject has received any prior pharmacotherapy, radiation therapy or surgery for prostate cancer (the following exceptions are permitted):

    • Up to 3 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1, with no radiographic evidence of disease progression or rising prostate-specific antigen (PSA) levels prior to day 1;
    • Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1;
    • Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of day 1 and no evidence of disease progression during or after the completion of docetaxel therapy;
    • Up to 6 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to day 1;
    • Prior ADT given for \< 39 months in duration and > 9 months before randomization as /adjuvant therapy.
  • Subject had a major surgery within 4 weeks prior to day 1.
  • Subject received treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.
  • Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.
  • Subject received treatment with systemic greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.
  • Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.
  • Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an agent that inhibits the androgen receptor or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).
  • Subject received investigational agent within 4 weeks prior to day 1.
  • Subject has known or suspected or active .
  • Subject has a history of another invasive cancer within 3 years of screening, with the exception of fully treated cancers with a remote probability of recurrence.
  • Subject has \< 1500/μL, count \< 100000/μL or \< 10 g/dL (6.2 mmol/L) at screening. NOTE: May not have received any growth factors within 7 days or blood transfusions within 28 days prior to the hematology values obtained at screening.
  • Subject has total ≥ 1.5 x the (except subjects with documented Gilbert's disease), or or aspartate aminotransferase ≥ 2.5 x the upper limit of normal at screening.
  • Subject has creatinine > 2 mg/dL (177 μmol/L) at screening.
  • Subject has albumin \< 3.0 g/dL (30 g/L) at screening.
  • Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, brain arteriovenous malformation).
  • Subject has history of loss of consciousness or within 12 months prior to day 1.
  • Subject has cardiovascular disease, including the following:

    • Myocardial infarction within 6 months prior to screening;
    • Unstable angina within 3 months prior to screening;
    • class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multigated acquisition scan performed within 3 months before the randomization date demonstrates a ≥ 45%;
    • History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    • History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place;
    • Hypotension as indicated by systolic blood pressure \< 86 mm Hg at screening;
    • Bradycardia as indicated by a heart rate of ≤ 45 beats per minute on the screening ;
    • Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening.
  • Subject has gastrointestinal disorder affecting absorption.
  • Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
  • Subject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosis.
  • Subject has shown a reaction to the active pharmaceutical ingredient or any of the study capsule components.

Open-Label Phase:

  • Subject has taken commercially available enzalutamide
  • After unblinding, subject has started any new investigational agent or anti-neoplastic therapy intended to treat prostate cancer
  • Subject has any clinically significant disorder or condition including excessive alcohol or drug abuse, or secondary , which may interfere with study participation in the opinion of the investigator or medical monitor
  • Subject has current or previously treated brain metastasis or active leptomeningeal disease
  • Subject has a history of seizure or any condition that may increase the risk of seizure
  • Subject's disease has progressed radiographically during the double-blind period of the study and treatment with study drug was stopped prior to study-wide unblinding. (Note: Subject who progressed radiographically while in the double-blind period of the study and continued treatment per protocol is allowed to participate in the open-label phase.)
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)

    Participants received enzalutamide 160 mg capsules, orally once daily if tolerable, and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.

    Drug: Enzalutamide · Drug: Androgen deprivation therapy (ADT)

  • Placebo comparator
    Placebo Plus ADT (Double Blind Phase)

    Participants received enzalutamide-matching placebo capsules, orally once daily and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment."

    Drug: Placebo · Drug: Androgen deprivation therapy (ADT)

  • Experimental
    Enzalutamide Plus ADT (Open-Label Phase)

    Participants who received placebo in double-blind phase and remaind on study treatment until confirmed radiographic disease progression received enzalutamide and continued ADT in open-label phase. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.

    Drug: Enzalutamide

Interventions

  • Oral

    Also known as: Xtandi, MDV3100

  • DrugPlacebo

    Oral

  • DrugAndrogen deprivation therapy (ADT)

    All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.

06

What researchers measure

Primary outcomes

  1. Time to Prostrate Specific Antigen (PSA) Progression

    Time to PSA progression was calculated as the time from the date of randomization to the first observation of PSA progression. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 microgram/liter (μg/L) (2 nanogram/milliliter \[ng/mL\]) above the nadir (i.e., lowest PSA value observed post baseline or at baseline), which was confirmed by a second consecutive value at least 3 weeks later. Time to event analysis was performed using Kaplan-Meier estimates.

    Time frame: From the date of randomization to the first observation of PSA progression (up to 38 months)

Secondary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    An rPFS event was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by investigator or death (defined as death from any cause within 24 weeks from study drug discontinuation), whichever occurred first. Radiographic disease progression was defined as progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan. Time to event analysis was performed using Kaplan-Meier estimates.

    Time frame: up to 38 months

  2. Time to First Symptomatic Skeletal Event (SSE)

    Time to first SSE was defined as the time from randomization to the occurrence of the first SSE. SSE was defined as radiation or surgery to bone, clinically apparent pathological bone fracture or spinal cord compression. Time to event analysis was performed using Kaplan-Meier estimates.

    Time frame: Up to 38 months

  3. Time to Castration Resistance

    Castration resistance was defined as occurrence of radiographic disease progression, PSA progression or SSE with castrate levels of testosterone (\< 50 ng/dL). Time to castration resistance was defined as the time from randomization to the first castration resistant event (radiographic disease progression, PSA progression or SSE), whichever occurred first. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 μg/L (2 ng/mL) above the nadir (i.e., lowest PSA value observed post baseline or at baseline), which was confirmed by a second consecutive value at least 3 weeks later. Radiographic disease progression was defined as progressive disease by RECIST version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan. SSE was defined as radiation or surgery to bone, clinically apparent pathological bone fracture or spinal cord compression. Time to event analysis was performed using Kaplan-Meier estimates.

    Time frame: Up to 38 months

  4. Percentage of Participants With PSA Response (≥ 50%)

    The PSA response rate ≥50% is defined as the percentage of participants in the analysis population with maximal PSA declines of at least 50% at any time and at each visit for participants with detectable PSA at baseline and at least 1 post-baseline assessment.

    Time frame: Up to 38 months

  5. Percentage of Participants With PSA Response (≥ 90%)

    The PSA response rate ≥90% is defined as the percentage of participants in the analysis population with maximal PSA declines of at least 90% at any time and at each visit for participants with detectable PSA at baseline and at least 1 post-baseline assessment.

    Time frame: Up to 38 months

  6. Time to Initiation of New Antineoplastic Therapy

    Time to initiate of a new antineoplastic therapy (including cytotoxic and hormone therapies) was defined as the time interval from randomization to the date of the first dose administration of the first antineoplastic therapy. Time to event analysis was performed using Kaplan-Meier estimates.

    Time frame: Up to 38 months

  7. Percentage of Participants With Undetectable PSA (< 0.2 ng/mL)

    The PSA undetectable rate was defined as the percentage of participants with detectable (≥ 0.2 ng/mL) PSA at baseline, which became undetectable (\< 0.2 ng/mL) during study treatment. Only participants with detectable PSA at baseline was included in the analysis.

    Time frame: Up to 38 months

  8. Objective Response Rate (ORR)

    The ORR was defined as the percentage of participants with measurable disease at baseline who achieved a complete or partial response (CR or PR) in their soft tissue disease using the RECIST version 1.1 criteria, CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Up to 38 months

07

Results

Posted Nov 18, 2023

Participant flow

Chinese men with metastatic hormone sensitive prostate cancer were enrolled in the study.

Double Blind Phase
Participant flow — Double Blind Phase
MilestoneEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Enzalutamide Plus ADT (Open-Label Phase)
Started120600
Ongoing participants82180
Participants who received at least one dose of study drug119590
Completed000
Not completed120600
Withdrew: Progressive disease22260
Withdrew: Withdrawal by subject4110
Withdrew: Death110
Withdrew: Lost to follow-up100
Withdrew: Adverse event510
Withdrew: Ongoing participants82180
Withdrew: Miscellaneous310
Withdrew: Protocol deviation110
Withdrew: Did not take study drug110
Open Label Phase
Participant flow — Open Label Phase
MilestoneEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Enzalutamide Plus ADT (Open-Label Phase)
Started0023
Completed000
Not completed0023
Withdrew: Progressive disease007
Withdrew: Withdrawal by subject003
Withdrew: Death002
Withdrew: Ongoing participants0011

Outcome measures

PrimaryTime to Prostrate Specific Antigen (PSA) Progression

Time to PSA progression was calculated as the time from the date of randomization to the first observation of PSA progression. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 microgram/liter (μg/L) (2 nanogram/milliliter \[ng/mL\]) above the nadir (i.e., lowest PSA value observed post baseline or at baseline), which was confirmed by a second consecutive value at least 3 weeks later. Time to event analysis was performed using Kaplan-Meier estimates.

Time frame:
From the date of randomization to the first observation of PSA progression (up to 38 months)
Reported as:
Median · Months
Time to Prostrate Specific Antigen (PSA) Progression
MonthsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Time to Prostrate Specific Antigen (PSA) ProgressionNA (NA to NA)9.2 (6.54 to 17.48)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Log Rank · p = <0.0001 · Cox proportional hazard: 0.130 · 95% CI 0.076 to 0.222Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryRadiographic Progression-Free Survival (rPFS)

An rPFS event was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by investigator or death (defined as death from any cause within 24 weeks from study drug discontinuation), whichever occurred first. Radiographic disease progression was defined as progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan. Time to event analysis was performed using Kaplan-Meier estimates.

Time frame:
up to 38 months
Reported as:
Median · Months
Radiographic Progression-Free Survival (rPFS)
MonthsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Radiographic Progression-Free Survival (rPFS)NA (28.25 to NA)19.4 (13.63 to NA)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Log Rank · p = <0.0001 · Cox proportional hazard: 0.330 · 95% CI 0.196 to 0.556Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryTime to First Symptomatic Skeletal Event (SSE)

Time to first SSE was defined as the time from randomization to the occurrence of the first SSE. SSE was defined as radiation or surgery to bone, clinically apparent pathological bone fracture or spinal cord compression. Time to event analysis was performed using Kaplan-Meier estimates.

Time frame:
Up to 38 months
Reported as:
Median · Months
Time to First Symptomatic Skeletal Event (SSE)
MonthsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Time to First Symptomatic Skeletal Event (SSE)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Log Rank · p = 0.7279 · Cox proportional hazard: 0.789 · 95% CI 0.208 to 2.998Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryTime to Castration Resistance

Castration resistance was defined as occurrence of radiographic disease progression, PSA progression or SSE with castrate levels of testosterone (\< 50 ng/dL). Time to castration resistance was defined as the time from randomization to the first castration resistant event (radiographic disease progression, PSA progression or SSE), whichever occurred first. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 μg/L (2 ng/mL) above the nadir (i.e., lowest PSA value observed post baseline or at baseline), which was confirmed by a second consecutive value at least 3 weeks later. Radiographic disease progression was defined as progressive disease by RECIST version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan. SSE was defined as radiation or surgery to bone, clinically apparent pathological bone fracture or spinal cord compression. Time to event analysis was performed using Kaplan-Meier estimates.

Time frame:
Up to 38 months
Reported as:
Median · Months
Time to Castration Resistance
MonthsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Time to Castration ResistanceNA (31.18 to NA)8.3 (6.41 to 14.69)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Log Rank · p = <0.0001 · Cox proportional hazard: 0.172 · 95% CI 0.107 to 0.276Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryPercentage of Participants With PSA Response (≥ 50%)

The PSA response rate ≥50% is defined as the percentage of participants in the analysis population with maximal PSA declines of at least 50% at any time and at each visit for participants with detectable PSA at baseline and at least 1 post-baseline assessment.

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Percentage of Participants With PSA Response (≥ 50%)
Percentage of participantsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Percentage of Participants With PSA Response (≥ 50%)93.3 (87.3 to 97.1)80.0 (67.7 to 89.2)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Cochran-Mantel-Haenszel · p = 0.0036Stratified by volume of disease and previous docetaxel use during screening period. Parameter estimate: Difference in percentage
SecondaryPercentage of Participants With PSA Response (≥ 90%)

The PSA response rate ≥90% is defined as the percentage of participants in the analysis population with maximal PSA declines of at least 90% at any time and at each visit for participants with detectable PSA at baseline and at least 1 post-baseline assessment.

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Percentage of Participants With PSA Response (≥ 90%)
Percentage of participantsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Percentage of Participants With PSA Response (≥ 90%)86.7 (79.3 to 92.2)55.0 (41.6 to 67.9)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Cochran-Mantel-Haenszel · p = <0.0001Stratified by volume of disease and previous docetaxel use during screening period. Parameter estimate: Difference in percentage
SecondaryTime to Initiation of New Antineoplastic Therapy

Time to initiate of a new antineoplastic therapy (including cytotoxic and hormone therapies) was defined as the time interval from randomization to the date of the first dose administration of the first antineoplastic therapy. Time to event analysis was performed using Kaplan-Meier estimates.

Time frame:
Up to 38 months
Reported as:
Median · Months
Time to Initiation of New Antineoplastic Therapy
MonthsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Time to Initiation of New Antineoplastic TherapyNA (NA to NA)31.1 (NA to NA)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Log Rank · p = 0.5899 · Cox proportional hazard: 0.797 · 95% CI 0.350 to 1.819Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryPercentage of Participants With Undetectable PSA (< 0.2 ng/mL)

The PSA undetectable rate was defined as the percentage of participants with detectable (≥ 0.2 ng/mL) PSA at baseline, which became undetectable (\< 0.2 ng/mL) during study treatment. Only participants with detectable PSA at baseline was included in the analysis.

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Undetectable PSA (< 0.2 ng/mL)
Percentage of participantsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Percentage of Participants With Undetectable PSA (< 0.2 ng/mL)76.3 (67.4 to 83.8)22.8 (12.7 to 35.8)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 53.5 · 95% CI 40.1 to 66.9Stratified by volume of disease and previous docetaxel use during screening period. Parameter estimate: Difference in percentage
SecondaryObjective Response Rate (ORR)

The ORR was defined as the percentage of participants with measurable disease at baseline who achieved a complete or partial response (CR or PR) in their soft tissue disease using the RECIST version 1.1 criteria, CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Up to 38 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)
Objective Response Rate (ORR)76.6 (62.0 to 87.7)81.8 (59.7 to 94.8)
Statistical analysis
  • Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase) vs Placebo Plus ADT (Double Blind Phase) · Cochran-Mantel-Haenszel · p = 0.8312 · Difference in percentage: -5.2 · 95% CI -25.4 to 14.9Stratified by volume of disease and previous docetaxel use during screening period. Parameter estimate: Difference in percentage

Adverse events

Collected over From the first dose up to 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)21/119 (17.6%)42/119 (35.3%)115/119 (96.6%)
Placebo Plus ADT (Double Blind Phase)12/59 (20.3%)12/59 (20.3%)54/59 (91.5%)
Enzalutamide Plus ADT (Open-Label Phase)8/23 (34.8%)5/23 (21.7%)16/23 (69.6%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Enzalutamide Plus ADT (Open-Label Phase)
Cerebral infarctionNervous system disorders8/1191/591/23
Atrial fibrillationCardiac disorders0/1190/591/23
Vertigo positionalEar and labyrinth disorders0/1190/591/23
Urinary tract infectionInfections and infestations1/1191/591/23
Spinal compression fractureInjury, poisoning and procedural complications1/1190/591/23
Pathological fractureMusculoskeletal and connective tissue disorders0/1190/591/23
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1190/591/23
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1190/591/23
ParaplegiaNervous system disorders0/1190/591/23
Bone painMusculoskeletal and connective tissue disorders1/1192/590/23
Most frequent other events
Showing 10 of 68
Most frequent other events
EventEnzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Enzalutamide Plus ADT (Open-Label Phase)
Weight increasedInvestigations50/11919/594/23
AnaemiaBlood and lymphatic system disorders41/11923/596/23
HypertensionVascular disorders30/11919/592/23
HypertriglyceridaemiaMetabolism and nutrition disorders33/11912/593/23
HyperglycaemiaMetabolism and nutrition disorders31/11912/594/23
Alanine aminotransferase increasedInvestigations22/11915/593/23
Aspartate aminotransferase increasedInvestigations23/11913/593/23
Bone painMusculoskeletal and connective tissue disorders13/11912/592/23
Hot flushVascular disorders23/1199/592/23
Blood alkaline phosphatase increasedInvestigations9/11911/594/23

Baseline characteristics

The Intent-to-Treat (ITT) population included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(Years)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
Mean68.8 ± 7.468.7 ± 7.368.8 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
Female000
Male12060180
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
Hispanic or Latino000
Not Hispanic or Latino12060180
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
American Indian or Alaska Native000
Asian12060180
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Prior Docetaxel Use (yes or no)
Prior Docetaxel Use (yes or no)(Participants)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
Yes14822
No10652158
Volume of Disease (Low Vs High)
Volume of Disease (Low Vs High)(Participants)Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)Placebo Plus ADT (Double Blind Phase)Total
Low261440
High9446140
08

Study locations

28 sites
  • Site CN86022
    Beijing, China
  • Site CN86035
    Beijing, China
  • Site CN86024
    Changchun, China
  • Site CN86009
    Changsha, China
  • Site CN86016
    Changsha, China
  • Site CN86023
    Changsha, China
  • Site CN86025
    Fuzhou, China
  • Site CN86001
    Guangzhou, China
  • Site CN86028
    Hangzhou, China
  • Site CN86036
    Hangzhou, China
  • Site CN86004
    Nanchang, China
  • Site CN86002
    Shanghai, China
  • Site CN86003
    Shanghai, China
  • Site CN86010
    Shanghai, China
  • Site CN86013
    Shanghai, China
  • Site CN86014
    Shanghai, China
  • Site CN86027
    Shanghai, China
  • Site CN86020
    Shenyang, China
  • Site CN86011
    Shenzhen, China
  • Site CN86032
    Suzhou, China
  • Site CN86012
    Tianjin, China
  • Site CN86005
    Ürümqi, China
  • Site CN86019
    Wuhan, China
  • Site CN86026
    Wuhan, China
  • Site CN86021
    Wuxi, China
  • Site CN86038
    Xi'an, China
  • Site CN86017
    Zhengzhou, China
  • Site CN86029
    Zhengzhou, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Nov 2022, 38 months.

Results were first posted in Nov 2023, 1 year after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 38 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2019
First posted
Sep 3, 2019
StartActual
Sep 11, 2019
Primary completionActual
Nov 18, 2022
CompletionEst.
Dec 31, 2028
Results first posted
Nov 18, 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04076059
Responsible party
Sponsor
First posted
Sep 3, 2019
Start date
Sep 11, 2019
Primary completion
Nov 18, 2022
Completion
Dec 31, 2028 (estimated)
Results posted
Nov 18, 2023
Last update
Oct 20, 2026

Study contacts

Medical Science Manager
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion